The robust shift in the pancreatic cancer cells from PD-L1 negative to PD-L1 positive may also explain the attenuated systemic anti-tumor immune response observed in the Pan02 model, compared to other cancers following IRE-based therapy. Here, CD274 is linked to neoplasm.